Related Experiment Videos

Cocktail modulator mixtures for overcoming multidrug resistance in renal cell carcinoma

D S Yu1, G H Sun, C P Ma

  • 1Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.

Urology
|August 12, 1999
PubMed
Abstract

Insights

Certain modulators like calcium antagonists, tamoxifen, and oligomycin can enhance chemotherapy effectiveness against renal cell carcinoma (RCC) by reversing multidrug resistance (MDR). These agents increase intracellular drug levels and cytotoxicity in RCC cells, particularly those with acquired resistance.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) significantly hinders effective chemotherapy for renal cell carcinoma (RCC).
  • Understanding modulators that can overcome MDR is crucial for improving RCC treatment outcomes.

Purpose of the Study:

  • To evaluate the impact of various modulators on intracellular drug accumulation in RCC cells.
  • To assess the ability of these modulators to reverse MDR and enhance the cytotoxicity of chemotherapeutic agents in both native and resistant RCC cell lines.

Main Methods:

  • Cytotoxicity of adriamycin was assessed in RCC 8701 and its MDR subline.
  • Fourteen MDR modulators, including calcium antagonists, were tested for their MDR-reversing activity using the microplate tetrazolium assay.

Main Results:

  • Calcium antagonists, tamoxifen, and oligomycin increased intracellular adriamycin concentration, peaking at 4 hours.
  • Verapamil, quinidine, tamoxifen, and oligomycin showed additive effects on adriamycin and vinblastine cytotoxicity in both native and MDR RCC cells.
  • MDR RCC cells exhibited greater sensitivity to modulator-enhanced cytotoxicity compared to native cells, with effects dependent on modulator dosage and duration.

Conclusions:

  • Calcium antagonists, tamoxifen, and oligomycin show promise as adjuncts to chemotherapy for overcoming drug resistance in RCC.
  • Further research is needed to optimize combination regimens, including timing, dosage, and frequency, for these modulators in clinical settings.

Related Concept Videos